NK1.1 Specific Neutra™ Antibody Products

Are you struggling with inconsistent NK cell functional assays or delayed therapeutic development due to antibody specificity challenges? Creative Biolabs' NK1.1 specific Neutra™ antibody products leverage advanced recombinant protein engineering and high-throughput validation to deliver superior affinity and specificity, enabling precise modulation of NK cell activity for accelerated research and therapeutic innovation.

Introduction to NK1.1

Natural Killer Cells (NK cells) are critical innate immune effectors responsible for targeting infected or malignant cells. NK1.1, a surface glycoprotein expressed on NK cells in strains such as C57BL/6, functions as a defining marker and modulates cellular activity through ligand interactions. As a member of the C-type lectin-like receptor family, NK1.1 participates in balancing activating and inhibitory signals that govern NK cell cytotoxicity and immune surveillance.

Fig.1 Role of NK1.1 signaling in HF development and the progression of pulmonary inflammation and remodeling.¹

• Structural Insights

NK1.1 is a transmembrane protein comprising a conserved extracellular lectin-like domain, a stalk region, and a cytoplasmic tail lacking intrinsic signaling motifs. It forms homodimers on the NK cell surface, interacting with ligands such as Ocil/Clr-b to regulate inhibitory signaling. Structural studies reveal that NK1.1's extracellular domain adopts a β-sheet fold critical for ligand recognition, enabling selective targeting for functional modulation.

• Related Signaling Pathways

NK1.1 integrates signals from both activating (e.g., NKG2D, DNAM-1) and inhibitory receptors (e.g., Ly49). Ligand binding to NK1.1 recruits phosphatases like SHP-1 via adaptor proteins, suppressing downstream kinases (e.g., Syk, ZAP70) to dampen cytotoxicity. Conversely, disengagement of inhibitory ligands unleashes activating pathways, triggering perforin/granzyme release and cytokine production. This dynamic equilibrium ensures controlled immune responses against pathological threats.

• Associated Pathologies

Dysregulated NK1.1 signaling is implicated in immune evasion mechanisms of cancers (e.g., leukemia, melanoma) and viral persistence (e.g., CMV, influenza). Tumors overexpressing NK1.1 ligands evade NK cell surveillance by suppressing cytotoxicity, while viral infections downregulate ligands to escape detection. Conversely, autoimmune disorders like lupus correlate with hyperactive NK cell responses linked to NK1.1 signaling imbalances.

Applications of NK1.1 Neutralizing Antibodies

• Oncology: Enhancing Tumor Immunity

Blocking NK1.1-mediated inhibitory signals restores NK cell cytotoxicity against ligand-deficient tumors. In melanoma models, anti-NK1.1 antibodies synergize with checkpoint inhibitors to reduce metastasis and improve survival rates.

• Infectious Disease: Controlling Viral Spread

NK1.1⁺ NK cells are pivotal in early viral containment. Neutralizing antibodies facilitate studies on NK cell exhaustion in chronic infections (e.g., HIV), guiding therapeutic strategies to sustain antiviral activity.

• Autoimmunity: Restoring Immune Balance

In rheumatoid arthritis, anti-NK1.1 antibodies mitigate tissue damage by dampening hyperactive NK cell responses, offering insights into targeted immunosuppressive therapies.

• Therapeutic Development: Streamlining Validation

These antibodies are indispensable for screening drug candidates that modulate NK cell activity, reducing timelines for IND-enabling studies.

Our Anti-NK1.1 Antibodies

Creative Biolabs' anti-NK1.1 neutralizing antibodies are rigorously validated for specificity and functionality. These antibodies enable:

- Selective Depletion: Temporarily eliminate NK1.1⁺ cells in vivo to dissect their roles in disease models.

- Functional Blockade: Inhibit ligand binding to study signaling pathways or enhance cytotoxicity in immunotherapy.

- Flow Cytometry & Imaging: Track NK1.1 expression dynamics during immune responses with superior signal-to-noise ratios.

Engineered for minimal cross-reactivity, these antibodies support applications from basic research to preclinical trials, ensuring reproducibility across assays like ADCC, ELISA, and single-cell sequencing.

Creative Biolabs' NK1.1 specific Neutra™ antibody products combine scientific rigor with versatility, empowering breakthroughs in immunotherapy and immune mechanism research.

Contact our team today to explore custom solutions tailored to your project.

REFERENCE

1. He, Xiaochen, et al. "Inhibition of NK1. 1 signaling attenuates pressure overload-induced heart failure, and consequent pulmonary inflammation and remodeling." Frontiers in Immunology 14 (2023): 1215855. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2023.1215855IF